Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02848443

Recruitment Status : Completed

First Posted : July 28, 2016

Last Update Posted : June 30, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

ADIR, a Servier Group company

Information provided by (Responsible Party):

Servier ( Institut de Recherches Internationales Servier )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	August 1, 2019
Actual Study Completion Date :	April 9, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Argiles G, Andre T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.

To Top